News | July 26, 2023
Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
